3 news items
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
13 May 24
- Investigational New Drug
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
STRO
2 Apr 24
for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical-development
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
STRO
25 Mar 24
.An Investigational New Drug (IND) application submission is planned for treatment of non-small cell lung cancer (NSCLC
- Prev
- 1
- Next